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Alterations in the function of multiple genes are required for the
full development of oncogenic phenotype in humans and other
mammals (Knudson, 1971; Vogelstein et al, 1987). In the case of
tumour-suppressor genes, it is now clear that loss of function can
not only occur through allelic loss or mutation, but also through
loss of function mediated by DNA methylation (Baylin, 1992;
Szyf, 1994; Merlo et al, 1995). The p16 gene (CDKN2/MTS-
1/INK4A) is one such gene. This gene acts to inactivate CDK4 and
CDK6 cyclin-dependent kinases and, hence, controls the entry of
cells from G1 to S-phase (Kamb, 1995; Hara et al, 1996). As such,
it is a prime candidate as a tumour-suppressor gene. However,
whereas this gene was found to be subject to frequent homozygous
deletion in tumours, point mutations were not commonly detected.
Consequently, the role of p16 as a tumour suppressor was ques-
tioned until it was shown that the p16 gene was also frequently
inactivated through a process involving DNA methylation without
point mutation (Merlo et al, 1995; Herman et al, 1996a).
In human breast tumours, it has been reported that > 30% of
primary tumours and many tumour-derived cell lines have inactive
methylated copies of the p16 gene (as assayed at only a few sites
using methylation-sensitive restriction endonucleases) (Merlo et
al, 1995). Herman et al (1996b) have further shown by bisulphite
genomic sequencing that in a tumour cell line (H157) a region of
the p16 gene becomes completely methylated at all CG dinu-
cleotides. Extrapolating from this finding, they developed an assay
that will detect a very small proportion of tumour cells containing
methylation at all CG sites as a sensitive method of detecting
minimal residual disease. This method uses polymerase chain
reaction (PCR) primers that amplify specifically from the fully
CG-methylated form of the gene after bisulphite conversion of
unmethylated cytosines to uracils (Frommer et al, 1992). Using
this assay, they have demonstrated the presence in a series of
human tumour-derived cell lines and in some human tumours of
apparently fully CG-methylated forms of p16 and other genes
(Herman et al, 1996b).
Here, we report the results of genomic sequencing from DNA
from a series of human breast samples, both normal and tumour,
and demonstrate a common specific pattern of tumour-related
DNA methylation in a number of independent human breast
tumours. Rather than a non-specific methylation at CG dinu-
cleotides in this gene, this methylation has characteristics that
could better be explained as the product of a gene-specific alter-
ation in the local secondary structure of the promoter/exon1 region
that transforms it into a highly efficient substrate for asymmetric
de novo methylation.
MATERIALS AND METHODS
Human tissue specimens were portions of samples provided for
routine pathology assessment that were in excess of the require-
ments for that purpose and were obtained with the approval of the
relevant ethics committees. All samples were stored at –70°C until
DNA was extracted by the guanidine isothiocyanate/caesium chlo-
ride method for the isolation of both RNA and DNA (Chirgwin et
al, 1979), and further purified by extraction with phenol/chloro-
form. For genomic sequencing of sites of DNA methylation, 5 mg
of genomic DNA was modified with metabisulphite after alkali
denaturation using five or six cycles of 94°C for 3 min, 55°C for
57 min and subsequently desulphonated as described previously
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Locked Bag No. 1, A’Beckett Street, Melbourne, Victoria 8006, Australia(Woodcock et al, 1997). Modifications included an internal control
and a linearized plasmid DNA containing an human CpG island
insert (from the 5¢ end of an L1 repeat) as used in previous studies
using bisulphite genomic sequencing (Woodcock et al, 1997,
1998). Only modifications in which clones amplified from this
control sequence were found to contain < 0.2% residual cytosines
(i.e. effectively completely modified) were used for amplification
for genomic sequencing of methylation sites. In all instances,
each set of clones are derived from multiple template modification
and amplification reactions done on different days. For ampli-
fication of the p16 sequences, the primers used were
5¢-AGGATTTGAGGGA(C/T)AGGG-3¢ and 5¢-CCAATTCCC-
CT(G/A)CAAACTTC-3¢. These corresponded to bases 1059–
1073 of the human p16 promoter/exon 1 CpG island region
(GenBank:HSPRCDNK2) and the complement of bases 308–327
from the overlapping GenBank entry for human p16 exon 1
(HSPCDK1). PCR products were cloned into pGEM-T vector
(Promega) and transformed into highly electrocompetent DH12S
Escherichia coli host cells. Random white colonies were screened
for the correctly sized insert (70–100% of those screened) and
sequenced with the forward and reverse universal primers using
the ABI 377 system using dye terminator chemistry (Applied
Biosystems). Genomic sequencing from the 5¢ hypermethylated
CpG island region of human L1 elements was performed as
described previously (Woodcock et al, 1997).
RESULTS
In the bisulphite method for the genomic sequencing of sites of
DNA methylation, unmethylated cytosines are converted to uracils
and, through subsequent PCR amplification, to thymines
(Frommer et al, 1992). After this process, the two strands of any
region of duplex DNA are no longer complementary (unless all
cytosines in the sequence are methylated). Consequently, different
primers are required to amplify the ‘top’ and ‘bottom’ strands of
any DNA sequence after bisulphite modification.
However, if unwarranted a priori assumptions as to methylation
status of any DNA sequence are used in primer design, it is possible
[and even likely (Herman et al, 1996b)] that PCR will only amplify
from some subset of DNA strands whose methylation pattern may
not necessarily reflect the methylation of most DNA from that
sample. In this study, PCR primers for the p16 gene were designed
so that they would be able to prime amplification from both modi-
fied and unmodified (native) forms of the target sequence, irrespec-
tive of methylation status of any or all cytosines in the primer
sequences (Woodcock et al, 1997, 1998). This was achieved by
choosing a site for the forward primer that was rich in guanines and
contained the minimum number of cytosines (and also lacked
simple sequence tracts). Any cytosine in the PCR forward primers
was synthesized as a degenerate site (C or T), irrespective of dinu-
cleotide context. For the reverse primer complementary to the
strand amplified, this strategy for primer design results in a primer
rich in cytosines and with any guanines as a degenerate G or A. No
assumptions were made that methylation was only in CG dinu-
cleotides because it now appears that, in some instances,
mammalian cells can have methylation at sites other than CG dinu-
cleotides (Woodcock et al, 1987, 1997; Toth et al, 1990; Clark et al,
1995; Snibson et al, 1995).
The sequence of the region amplified from the p16 gene is
shown in Figure 1. This figure illustrates the positions of sequence
features such as the ATG initiation codon for the main transcript
from the p16 gene (Mao et al, 1995), the two pairs of tandem
repeats, and three SP1 core consensus sequences (Minth and
Dixon, 1990; Thiesen and Bach, 1990; Merchant et al, 1991).
Using native (not bisulphite-modified) normal human DNA as a
template, PCR amplification with these primers generated clones
from the p16 gene that were identical in sequence to the cor-
responding GenBank entries (Figure 2).
DNA from four normal human breast samples (from reductive
mammaplasty) and from nine breast tumours were modified with
bisulphite and the modified form of DNA strands from the p16
gene amplified with PCR primers as described above. A total of
137 independent clones derived from the tumour DNAs and 32
clones from the normal breast DNAs were sequenced. Only clones
from modification reactions in which DNA derived from the
internal control sequence had been effectively converted were
analysed. All sets of clones are derived from two or more indepen-
dent modification and amplification reactions
Clones of the PCR product from bisulphite-modified normal
breast DNAs showed this region was essentially devoid of methy-
lation except for low levels of residual cytosines in apparently
random sites (Figure 2). This was also the case for clones from
four of the tumour sample DNAs. The p16 sequences amplified
from human embryonic fibroblast DNA were also unmethylated
(DW, unpublished data). However, clones from five of the inde-
pendent tumour samples showed a consistent pattern of methyla-
tion principally in the same set of nine sites (Figure 2). The regions
of the tumour-derived p16 clones aligned in this figure contain
eight of the nine consistently methylated sites, the other site of
methylation being at base no. 356 that is immediately adjacent to
the reverse primer sequence (Figure 1).
All the tumour samples contained unmethylated clones, as
expected, as any surgical sample is likely to contain a mixture of
normal and tumour cells, with the relative proportion of methy-
lated clones possibly reflecting the proportion of tumour cells in
the specimen. In the tumour samples ts18, ts23, ts24, ts34 and
ts43, these sites were coordinately methylated in 11%, 24%, 10%,
18% and 17% of clones, respectively, with all but one of the clones
having all nine of these residual cytosines. There was also another
pattern of coordinated methylation observed in 11% of clones
from ts34 (methylation at base numbers 204, 244 and 272) that
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Figure 1 Region amplified from the promoter/exon1 region of the human
p16 gene. The sequence is derived from two overlapping GenBank entries:
HSPCDNK2 and HSPCDK1. The PCR primer regions are shown with the
dotted underlining. This region contains two direct repeats of 24 bp and 9 bp,
with the first of each pair shown with single underlining and the second of
each pair with double underlining. SP1 core consensus sequences (Minth
and Dixon, 1990; Thiesen and Bach, 1990; Merchant et al, 1991) are shown
in italics and the ATG initiation codon as bold capitals. The predominant
methylation pattern contains all of the capitalized Cs between the primers
except those at bases 204 and 272. The minor methylation pattern found in
ts34 only consisted of the Cs at bases 204, 244 and 272was not observed in any of the clones from the other modified
DNAs. In these two distinct methylation patterns observed in the
ts34 clones, base 244 was the only methylated site common to both
patterns (Figure 2). In the remaining sets of tumour-derived p16
clones that did not exhibit discrete methylation patterns, there was
a slightly higher proportion of (apparently random) methylated
bases present overall than in clones from normal breast DNAs.
However, methylation levels were somewhat lower overall than in
the tumours with discrete methylation.
In the tumour-derived clones exhibiting discrete methylation
patterns, a high proportion of residual cytosines (methylation sites)
were on non-CG contexts (Figures 1 and 2). In the predominant
tumour methylation pattern, five out of nine sites in the region
amplified were in mCG dinucleotides, but three out of nine were in
mCTG contexts and one in what would have been mCCTTCG. In
the secondary methylation pattern found in some clones from ts34,
the original sequence contexts would have been mCACG,  mCTG
and  mCACCG. The few random residual cytosines that were
observed in clones from normal breast DNAs were almost exclu-
sively in the context of CG dinucleotides (not illustrated).
To test whether this unusually high proportion of non-CG
methylation observed in the p16 gene from these tumour DNAs
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Figure 2 Alignment of p16 sequence data from PCR products from bisulphite-modified normal and tumour DNAs in the region of bases 174–210 and
229–278. These regions contain eight out of the nine consistently methylated sites observed in these clones. Only very low levels of random methylation were
detected between bases 1 and 173, 211 and 228, and 279 and 355. The genomic sequence from the GenBank entries (Figure 1) is given across the top. An
identical sequence was found in clones from the human p16 gene amplified using these primers from unmodified DNA from non-transformed human embryonic
fibroblasts (second line). Below this is the sequence as it would appear if every C were converted to a T (complete conversion of a completely unmethylated
form of the sequence). Underneath this is the aligned compilation from all of the clones from modified normal breast DNAs (‘nb1’ to ‘nb4’) and from tumour
DNAs (‘ts18’ through to ‘ts43’). A dash indicates identity with the sequence expected for the full bisulphite conversion of the unmethylated form of the p16
sequence. The clones from each tumour DNA are grouped with respect to sequence identity within that group. The total clones sequenced from each tumour
DNA are shown together with the per cent of clones in each group showing sequence identity within these two regions. Four of the tumour-derived specimens
were basically unmethylated as were those from normal breast DNAs (i.e. low levels of random residual cytosines). Clones from the other five tumours were
either unmethylated (presumably derived from normal cells in the surgical sample) or methylated with a consistent pattern of residual cytosines. Five other
clones derived from four different template DNAs were excluded from this analysis. These contained regions with strings of adenine substitutions reminiscent of
PCR amplification from non-instructional lesions or abasic sites (Strauss, 1991). Complete alignments of all clones are available from the authors on requestmight reflect some widespread deregulation (or misregulation) of
the methylation processes, DNA sequences from the methylated
CpG island region of human L1 dispersed repeat elements
(Woodcock et al, 1997) were amplified, cloned and sequenced.
This allowed the sampling from multiple dispersed sites of methy-
lation through the genome rather than from just a single site as
would be the case with a unique protein coding sequence. In
clones from these sequences amplified from bisulphite-modified
DNAs from normal breast samples, a total of 37 consistently
methylated sites were observed in a 460-bp region with an average
55.5% residual cytosines at these sites. (These are observed
frequencies of cytosines only with no correction having been made
for sequence variations within the repeat sequence family.)
L1 clones from two tumour DNAs with basically unmethylated
p16 genes (ts21 and ts30) had 34.0% residual cytosines present on
average at these sites, whereas the average for the clones from the
tumours with methylated p16 was 42.5% residual cytosines. The
methylation levels in dispersed repeats are likely to reflect average
methylation levels in total genomic DNA, and are consistent with
previous observations that tumours frequently have lower total
genomic methylation levels which may be accompanied by
increased methylation in some normally unmethylated CpG island
regions (such as the p16 promoter) (reviewed by Szyf, 1994). The
relative levels of methylated cytosines at each of these consistently
methylated sites in L1 elements from DNAs from normal and
tumour-derived DNAs (with and without p16 methylation) are
shown in Figure 3. All 37 of the consistently methylated sites in
clones from the L1 repeats from both normal and tumour DNAs
were in CG dinucleotides. However, there were some methylated
non-CG sites observed. The occurrence of sites of non-CG methy-
lation, however, was suggestive of individual polymorphisms in
the control of epigenetic modification. For example, seven out of
nine clones from one normal breast sample (nb1) had a mCmCA
sequence. This site was also methylated in four out of nine and one
out of ten clones from two other sets of normal breast-derived
clones (nb2 and nb5 respectively), but absent from clones from the
fourth normal breast sample and also from all tumour-derived
clones. Also, the tumour DNA ts30 in which the p16 gene was
unmethylated had two mCAG sites, one mCTT and one mCATTAG
site in up to one-third of clones (not illustrated). In addition, at site
no. 15 in ts30 clones, 0 out of 12 clones had a residual cytosine at
this CG dinucleotide. Rather, five of these clones had a residual
cytosine as the prior base (i.e. originally mCCG rather than CmCG).
DISCUSSION
Using genomic sequencing of DNAs from human clinical speci-
mens, we have observed a common pattern of DNA methylation in
the p16 gene from a series of independent breast tumour samples.
This methylation pattern is of unusual sequence specificity and
contains a high proportion of methylation at asymmetric sites. We
consider that this unusual methylation pattern is not an experi-
mental artefact for the following reasons:
1. The PCR product from modifications of human genomic
DNAs were not used unless clones from the control plasmid
were effectively modified (< 0.2% residual cytosines
excluding sites of endogenous E. coli dcm methylation)
(Woodcock et al, 1997).
2. In clones from modified DNAs from four normal breast
samples and from four of the breast tumours, the p16 gene was
essentially unmethylated (in a total of 72 independent clones
comprising 33 from normal breast samples and 39 from four
tumour samples). Thus, methylation at the specific set of sites
observed in these five breast tumours is specific to DNA from
these tumours and cannot represent some region that is intrin-
sically resistant to bisulphite modification.
Hence, it appears that the residual cytosines present in clones
from modified DNAs from some human breast tumours represent
a characteristic tumour-specific epigenetic modification to the
DNA. Although clones from one of the tumour specimens showed
evidence of a second pattern of DNA methylation in the p16 gene,
clones with the common predominant pattern of methylation were
also present. (It is conceivable that these two methylation patterns
represent two independent lines of oncogenic evolution in this
particular tumour.)
Herman et al (1996b) have shown that, in some human tumour-
derived cell lines and some clinical specimens, the p16 gene can
be present with complete methylation of CG dinucleotides. We
cannot say from these data that the breast tumour DNAs used in
this study do not contain some p16 sequences with complete
methylation at all of the CG dinucleotides. If copies of this gene
with complete CG methylation were present at, for example,
<10% of the frequency of sequences with the methylation pattern
we have observed, we would have a low probability of recovering
them, considering also that these clinical samples contain a
mixture of normal cells. However, we have shown previously that
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Figure 3 Proportion of clones with residual cytosines in each of the consistently methylated sites from the methylated CpG island region from human L1
dispersed repeats. Values are given as percentage of the total clones with cytosines averaged over all the clones from normal breast DNAs (n), the clones from
tumours with methylated p16 gene ( ), and the clones from tumour DNAs where p16 exhibited low levels of random methylation (as in normal breast) (n n). The
x-axis represents the numbering from 5¢ to 3¢ of the consistently methylated CG sites. Sets of full sequence data relating site number to base number are
available on requestthe PCR amplification and cloning methodology employed here
does not bias the data through the selective recovery of clones
from less methylated forms of the target sequence (Woodcock et
al, 1997). It has also been shown that, during adaptation of cells to
in vitro culture, many normally unmethylated sites in CpG island
sequences can become methylated (Antequera et al, 1990). The
observation of complete methylation in all CG dinucleotides in the
p16 gene from a human tumour-derived cell line is more likely to
represent a later stage in the evolution of epigenetic modification
of this CpG island rather than an artefact of in vitro culture. The
ability to amplify from primary human tumours using PCR
primers specific for the bisulphite-modified form of fully CG
methylated  p16 gene argues strongly for the presence of some cells
within primary tumours with this pattern of methylation (Herman
et al, 1996b). The absence of clones with such a methylation
pattern in this study could be due to such cells being in relatively
low abundance. This would not be inconsistent with total methyla-
tion at CG dinucleotides representing an important and character-
istic stage of tumour evolution, however an assessment of the
minimal residual disease using an assay that identifies cells with
total methylation of p16 would fail to detect tumour cells with
other patterns of methylation.
The major concentration of methylated sites in the p16
promoter/exon 1 region examined in this study is in a region
containing two 9-bp direct repeats separated by 9 bp (Figure 1 and
Figure 2). Overlapping with this central region and the 3¢ repeat is
a SP1 core consensus site (Minth and Dixon 1990; Thiesen and
Bach, 1990; Merchant et al, 1991). Methylation in CG dinu-
cleotides has been shown not to affect SP1 binding (Harrington et
al, 1988). The presence of SP1 sites has also been shown to protect
against de novo methylation and to induce demethylation adjacent
to the SP1 site (Brandeis et al, 1994; Macleod et al, 1994; Silke et
al, 1995). There are also two other SP1 consensus sites 70–100 bp
upstream in two 24-bp tandem repeats with the more proximal
repeat containing the p16 ATG initiation codon plus the first of the
tumour-specific methylation sites. In this instance, this concentra-
tion of SP1 binding sites has not prevented tumour-specific methy-
lation in this p16 CpG island region.
Methylation, particularly the high concentration of non-CG
methylation observed in the p16 gene region, was not part of some
general non-specific epigenetic modification of the tumour
genomes. When we sampled the sequence specificity of methyla-
tion in multiple regions of the normal and tumour breast DNAs
using the CpG island region from the 5¢ end of human L1 repeats,
methylation was consistently found at more sites than we observed
previously in L1 elements from non-transformed human embry-
onic fibroblasts (Woodcock et al, 1997). In this L1 region, 29
consistently methylated sites were observed in embryonic fibro-
blast DNA as opposed to the 37 observed in this study with DNA
from normal human breast. Also, for the L1 elements from embry-
onic fibroblasts, 4 out of 29 consistently methylated positions were
in non-CG sites, whereas, in this study, the consistently methylated
sites were all in CG dinucleotides. However, some specific sites of
non-CG methylation were present but these seemed to be specific
to the individual, and may represent polymorphisms in genetic
factors that determine epigenetic events. However, overall, there is
no evidence for a general increase in non-CG methylation in the
genome of those tumours that have a high proportion of non-CG
methylation in their p16 genes.
There is now evidence that mice (and presumably all other
mammals) have more than one DNA methyltransferase gene. ES
cells from complete knockouts of the know DNA methyltrans-
ferase gene retain residual DNA methylation as well as the ability
to methylate sequences de novo (Lei et al, 1996; Tucker et al,
1996). This residual DNA methyltransferase gene has been
suggested to represent the activity responsible for the wave of de
novo methylation that occurs in the genome of the preimplantation
embryo (Monk, 1990). However, the discrete methylation patterns
observed in p16 gene from tumour DNAs with their high propor-
tion of methylation at non-CG sites is very different from the
specificity of methylation in methyltransferase-knockout ES cells.
This methylation is apparently totally CG-specific and it appears
to be randomly positioned within the set of sites that are methy-
lated in the normal adult mouse genome (Woodcock et al, 1998).
Rather, the high proportion of non-CG methylation in the tumour
p16 genes is more likely to be related to the process whereby sites
of CNG methylation in transfected plasmid DNAs can be main-
tained over many cell generations in mouse cells in culture (Clark
et al, 1995).
For a distinct methylation pattern to be present, there must be
some mechanism that efficiently restores this methylation in the
daughter strands after each round of replication. Otherwise, such a
methylation pattern would rapidly be lost. Maintenance of DNA
methylation at any site in mammalian genomes in non-CG sites is
conceptually inherently more difficult than that in CG dinu-
cleotides in which there is the symmetrically placed mCG template
in the parental strand (Holliday and Pugh, 1975; Riggs, 1975). One
possible exception is methylation in CNG sequences (as in plant
DNAs) in which a parental template would be displaced by only
one base, although this is not a documented function of the
mammalian DNA methyltransferase. However, it has also been
shown that distortions of the DNA duplex that promote the extra-
helical extrusion of any cytosine base will render such a cytosine
an efficient substrate for de novo methylation (Smith et al, 1992;
Klimasauskas and Roberts, 1995; Laayoun and Smith, 1995). We
suggest that one possible explanation for the discrete pattern of
DNA methylation observed in the p16 gene in breast tumour
DNAs is that it is the result of sequence-specific protein binding
that induces the DNA duplex in this region to be distorted,
rendering certain specific bases efficient substrates for asymmetric
de novo methylation. If this were the case, inactivation of some
tumour-suppressor genes through DNA methylation would, thus,
be an active process in the tumour rather than through random
methylation at CG dinucleotides and, hence, be more amenable to
ultimate therapeutic manipulation.
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